Despite some limitations of these preclinical models, the present results demonstrate that the effects of BTK inhibition with BMS-986142 on antigen-specific BCR-mediated B-cell functions, IgG-containing IC signaling through FcγR in monocytic cells, and RANK-dependent osteoclastogenesis are anticipated to provide clinical benefit in the treatment of autoimmune disorders such as RA. This evidence concerns the gene TNFRSF11A and Autoimmunity.